132 related articles for article (PubMed ID: 21750291)
21. Rapid correction of metabolic acidosis in chronic renal failure: effect on parathyroid hormone activity.
Lu KC; Shieh SD; Li BL; Chu P; Jan SY; Lin YF
Nephron; 1994; 67(4):419-24. PubMed ID: 7969674
[TBL] [Abstract][Full Text] [Related]
22. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].
Hoshino J; Ubara Y; Takaichi K
Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034
[TBL] [Abstract][Full Text] [Related]
23. Tertiary hyperparathyroidism after renal transplantation--report of two cases and comparative study of parathyroid function with secondary hyperparathyroidism in chronic renal failure.
Uchida H; Andoh Y; Tomikawa S; Nishimura Y; Nagano T; Ichikawa N; Kikuchi K; Nomura Y; Degawa T; Meigata K
Transplant Proc; 1994 Aug; 26(4):2167-9. PubMed ID: 8066711
[No Abstract] [Full Text] [Related]
24. Considerations for the treatment of secondary hyperparathyroidism in renal failure.
Felsenfeld AJ
J Am Soc Nephrol; 1997 Jun; 8(6):993-1004. PubMed ID: 9189868
[No Abstract] [Full Text] [Related]
25. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis.
Drüeke TB; McCarron DA
N Engl J Med; 2003 Jul; 349(5):496-9. PubMed ID: 12890849
[No Abstract] [Full Text] [Related]
26. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis.
Natoli JL; Boer R; Nathanson BH; Miller RM; Chiroli S; Goodman WG; Belozeroff V
BMC Nephrol; 2013 Apr; 14():88. PubMed ID: 23594621
[TBL] [Abstract][Full Text] [Related]
27. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
Kazama JJ
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085
[TBL] [Abstract][Full Text] [Related]
28. The interaction of PTH and dietary phosphorus and calcium on serum calcitriol levels in the rat with experimental renal failure.
Martin-Malo A; Rodriguez M; Martinez ME; Torres A; Felsenfeld AJ
Nephrol Dial Transplant; 1996 Aug; 11(8):1553-8. PubMed ID: 8856210
[TBL] [Abstract][Full Text] [Related]
29. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
Tahara H
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
[TBL] [Abstract][Full Text] [Related]
30. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
[No Abstract] [Full Text] [Related]
31. [Parathyroidectomy in secondary hyperparathyroidism in chronic uremic patients under dialysis treatment. Development of the surgical strategy].
Zucchi C
Minerva Med; 1985 Mar; 76(9-10):397-401. PubMed ID: 3982697
[No Abstract] [Full Text] [Related]
32. Relation between Calcium, Phosphorus, Calcium-Phosphorus Index and iPTH in Chronic Kidney Disease Patients.
Adhikary LP; Yadava SK; Pokharel A; Khadka D; Thakur R
J Nepal Health Res Counc; 2015; 13(29):50-3. PubMed ID: 26411713
[TBL] [Abstract][Full Text] [Related]
33. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.
Naves-Díaz M; Passlick-Deetjen J; Guinsburg A; Marelli C; Fernández-Martín JL; Rodríguez-Puyol D; Cannata-Andía JB
Nephrol Dial Transplant; 2011 Jun; 26(6):1938-47. PubMed ID: 20513773
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of phosphate binders in adult patients with end stage renal disease receiving hemodialysis: a systematic review protocol.
Gasu V; Ashong M; Seferi A; Fitzpatrick A
JBI Database System Rev Implement Rep; 2018 Apr; 16(4):838-844. PubMed ID: 29634508
[TBL] [Abstract][Full Text] [Related]
35. Target levels for serum phosphorus and parathyroid hormone.
Qunibi W; Kalantar-Zadeh K
Semin Dial; 2011; 24(1):29-33. PubMed ID: 21324001
[No Abstract] [Full Text] [Related]
36. Relationship between serum intact parathyroid hormone and pruritus in hemodialysis patients.
Makhlough A; Emadi N; Sedighi O; Khademloo M; Bicmohamadi AR
Iran J Kidney Dis; 2013 Jan; 7(1):42-6. PubMed ID: 23314141
[TBL] [Abstract][Full Text] [Related]
37. Effect of calcium-channel blockers on calcium-phosphate metabolism in patients with end-stage renal disease.
Lippuner K; Zehnder HJ; Casez JP; Takkinen R; Descoeudres C; Jaeger P
Nephrol Dial Transplant; 1996 Jan; 11(1):70-4. PubMed ID: 8649655
[TBL] [Abstract][Full Text] [Related]
38. [Abnormalities in parathyroid hormone and calcitonin associated with uremia].
Okazaki R
Nihon Rinsho; 2004 Jun; 62 Suppl 6():169-72. PubMed ID: 15250289
[No Abstract] [Full Text] [Related]
39. Radioimmunoassay of carboxyl and amino terminal fragments of parathyroid hormone for the evaluation of secondary hyperparathyroidism in chronic renal failure.
Zanella MT; Silva MC; Peres RB; Ferreira SR; Draibe SA; Vieira JG
Braz J Med Biol Res; 1990; 23(3-4):235-43. PubMed ID: 2094538
[TBL] [Abstract][Full Text] [Related]
40. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
